Fig. 4: FOXA2 effects on proliferation and gene expression.
From: FOXA2 promotes metastatic competence in small cell lung cancer
a−f Subcutaneous tumor growth of FOXA2 KD and control cell lines (H1836, SHP-77). Tumor proliferation and growth as measured by tumor volume (a, d), BLI (b, e), and Ki67 score (c, f). Graphs indicate mean±S.D. (*** < 0.001, one-way ANOVA. a P = 4.2 × 10-4, b P = 0.012). g−i Pathway analysis of RNA-seq data on FOXA2 KD or OE cell lines compared to FOXA2 wild control. This GSEA analysis was based on the 3 replicates submitted for RNA-seq for each cell line. Top pathways downregulated in FOXA2 KD cell lines (H1836 (g), SHP-77 (h)) and upregulated in the FOXA2 OE cell line (H1963 (i)) are indicated.”Set size” refers to the total number of genes in the pathway and the exact number and genes can be traced in the supplementary data. j Upregulated pathways in met-associated primary tumor compared to never-met primary tumor. This analysis is generated from 1 RNA-seq data set (the same set from Fig. 2) of clinical samples using GSEA pathway analysis. N.s. Not significant, NES normalized enrichment score.
